{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:37:36Z","timestamp":1787027856259,"version":"build-2736575974"},"reference-count":22,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab. The optimal duration of eculizumab in treating patients with aHUS remains poorly defined. Methods: We conducted a multicenter retrospective study in the Arabian Gulf region for children of less than 18 years of age who were diagnosed with aHUS and who discontinued eculizumab between June 2013 and June 2021 to assess the rate and risk factors of aHUS recurrence. Results: We analyzed 28 patients with a clinical diagnosis of aHUS who had discontinued eculizumab. The most common reason for the discontinuation of eculizumab was renal and hematological remission (71.4%), followed by negative genetic testing (28.6%). During a median follow-up period of 24 months after discontinuation, 8 patients (28.5%) experienced HUS relapse. The risk factors of recurrence were positive genetic mutations (p = 0.020). On the other hand, there was no significant relationship between the relapse and age of presentation, the need for acute dialysis, the duration of eculizumab therapy before discontinuation, or the timing of eculizumab after the presentation. Regarding the renal outcomes after discontinuation, 23 patients were in remission with normal renal function, while 4 patients had chronic kidney disease (CKD) (three of them had pre-existing chronic kidney disease (CKD) before discontinuation, and one case developed a new CKD after discontinuation) and one patient underwent transplantation. Conclusions: The discontinuation of eculizumab in patients with aHUS is not without risk; it can result in HUS recurrence. Eculizumab discontinuation can be performed with close monitoring of the patients. It is essential to assess risk the factors for relapse before eculizumab discontinuation, in particular in children with a positive complement variant and any degree of residual CKD, as HUS relapse may lead to additional loss of kidney function. Resuming eculizumab promptly after relapse is effective in most patients.<\/jats:p>","DOI":"10.3390\/children9111734","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T02:33:10Z","timestamp":1668393190000},"page":"1734","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome"],"prefix":"10.3390","volume":"9","author":[{"given":"Saeed","family":"AlZabali","sequence":"first","affiliation":[{"name":"Pediatric Nephrology Department, King Fahad Medical City, Riyadh 11525, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawsan","family":"AlBatati","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, King Fahad Medical City, Riyadh 11525, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawla","family":"Rahim","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, King Fahad Medical City, Riyadh 11525, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Faqeehi","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, King Fahad Medical City, Riyadh 11525, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubaker","family":"Osman","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, King Fahad Medical City, Riyadh 11525, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Bamhraz","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Children\u2019s Hospital-McMaster University, Hamilton, ON L8N 3Z5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Saleh","sequence":"additional","affiliation":[{"name":"Section of Medical Genetics, Children Hospital, King Fahad Medical City, Riyadh 12231, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-8926","authenticated-orcid":false,"given":"Jameela A.","family":"Kari","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, Faculty of Medicine and Pediatric Nephrology Center of Excellence, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-4539","authenticated-orcid":false,"given":"Majed","family":"Aloufi","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology and Pediatric Kidney Transplantation, Prince Sultan Military Medical City, Riyadh 12231, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loai","family":"Eid","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, Dubai Hospital, Dubai 14660, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haydar","family":"Nasser","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, King Fahad Military Hospital, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakr","family":"Imam","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology and Hypertension, Sidra Medicine, Doha P.O. Box 26999, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Entesar","family":"AlHammadi","sequence":"additional","affiliation":[{"name":"Pediatrics Nephrology Department, Dubai Health Authority, Dubai 14660, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alkandari","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Mubarak Al-Kabeer Hospital, Street 103, Jabriya 46300, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-5609","authenticated-orcid":false,"given":"Mohammed","family":"Al Riyami","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, The Royal Hospital, P.O. Box 1331, Muscat 111, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1516-3393","authenticated-orcid":false,"given":"Sidharth","family":"Sethi","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Kidney Institute, Medanta, The Medicity Hospital, Gurgaon 122007, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4168-3277","authenticated-orcid":false,"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[{"name":"Division of Nephrology, The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4291-8536","authenticated-orcid":false,"given":"Khalid A.","family":"Alhasan","sequence":"additional","affiliation":[{"name":"Pediatric Department, College of Medicine, King Saud University, Riyadh 12231, Saudi Arabia"},{"name":"Pediatric Kidney Transplant Section, Organ Transplant Center, King Faisal Specialist Hospital and Research Center, Riyadh 12231, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkarim","family":"AlAnazi","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, King Fahad Medical City, Riyadh 11525, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome: A Report of 10 Cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.RV17026","article-title":"Pathogenesis of Atypical Hemolytic Uremic Syndrome","volume":"26","author":"Yoshida","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ndt\/gfx196","article-title":"Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome","volume":"33","author":"Wijnsma","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3904\/kjim.2019.388","article-title":"Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome","volume":"35","author":"Lee","year":"2020","journal-title":"Korean J. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment","volume":"23","author":"Raina","year":"2018","journal-title":"Ther. Apher. Dial."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Menne, J., Delmas, Y., Fakhouri, F., Licht, C., Lommel\u00e9, \u00c5., Minetti, E.E., Prov\u00f4t, F., Rondeau, E., Sheerin, N.S., and Wang, J. (2019). Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1314-1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","article-title":"Eculizumab Use for Kidney Transplantation in Patients with a Diagnosis of Atypical Hemolytic Uremic Syndrome","volume":"4","author":"Siedlecki","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2015","journal-title":"Pediatr. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: A prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000492033","article-title":"When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies","volume":"48","author":"Olson","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1159\/000510612","article-title":"Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study","volume":"45","author":"Bamhraz","year":"2020","journal-title":"Kidney Blood Press. Res."},{"key":"ref_13","first-page":"310","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_14","first-page":"25","article-title":"Complete Renal Recovery Following Delayed Therapy with Eculizumab in Atypical Hemolytic Uremic Syndrome","volume":"2","author":"Alzabli","year":"2019","journal-title":"Asian J. Pediatr. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation","volume":"12","author":"Fakhouri","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ckj\/sfab005","article-title":"Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes","volume":"14","author":"Ariceta","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_18","first-page":"22","article-title":"The Most Expensive Drug in the World: To Continue or Discontinue, That Is the Question","volume":"33","author":"Khedraki","year":"2016","journal-title":"Fed. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ckj\/sfx024","article-title":"Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?","volume":"10","author":"Rodriguez","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00467-012-2276-8","article-title":"Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome","volume":"27","author":"Vilalta","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"ref_21","unstructured":"Licht, C., Ardissino, G., and Ariceta, G. (2014, January 11\u201316). Characteristics of 521 adult and pediatric patients in the Global aHUS Registry. Proceedings of the American Society of Nephrology (ASN) Kidney Week 2014 Annual Meeting, Philadelphia, PA, USA."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year\u2019s experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/9\/11\/1734\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:16:31Z","timestamp":1760145391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/9\/11\/1734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["children9111734"],"URL":"https:\/\/doi.org\/10.3390\/children9111734","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]}}}